RACHEL LAI: Open Payments
NPI 1205277753 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,515 in 62 payments from 13 companies in 2025. Trend: 2023 $2,636 · 2024 $2,937 · 2025 $1,515
Food & beverage: $1,515
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $248 |
| Actelion Pharmaceuticals US, Inc. | 8 | $241 |
| United Therapeutics Corporation | 9 | $234 |
| Abbott Laboratories | 3 | $232 |
| AstraZeneca Pharmaceuticals LP | 6 | $114 |
| Alnylam Pharmaceuticals Inc. | 4 | $109 |
| Merck Sharp & Dohme LLC | 5 | $92 |
| Novo Nordisk Inc | 3 | $73 |
| SCPHARMACEUTICALS INC. | 3 | $52 |
| CVRx, Inc. | 10 | $49 |
Products named: UPTRAVI, Kerendia, CARDIOMEMS, Tyvaso, WAINUA, AMVUTTRA, FUROSCIX, ONPATTRO.
Industry payments across TX — which companies pay providers there.
